Skip to main content
SpringerLink
Log in

Beyond Lipid Lowering: The Anti-Hypertensive Role of Statins

  • REVIEW
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Introduction

The management of the hypercholesterolemic patient has evolved tremendously with the introduction of the HMG-CoA Reductase inhibitors, a class of drugs better known as the statins. Statins modify cholesterol metabolism by inhibiting the rate-limiting enzyme of cholesterol biosynthesis, producing greater decreases in plasma cholesterol levels than previously realized with hypolipidemic therapy. With the advent of the classic statin-megatrials such as the Scandinavian Simvastatin Survival Study (4S), WOSCOPS, CARE, and the more recent Heart Protection Study (HPS), the role of statins in both the primary and secondary prevention and ultimate risk reduction of patients with coronary disease has been firmly established.

Discussion

With an increase in use and popularity, a number of beneficial actions of the statins unrelated to their cholesterol-lowering ability have been reported. These effects have generated greater interest in the possible additional roles and indications for the use of these drugs. Of central focus in this paper is the cholesterol-independent benefit of this group of agents on the cardiovascular system, particularly on the lowering of systemic blood pressure. A number of hypotheses have been proposed for this action and these shall be reviewed within this paper.

Conclusion

We explore recent data that suggests that statins may provide substantial reduction of blood pressure in the hypertensive, hypercholesterolemic patient independent of their lipid-lowering effect. In addition, we review several notable publications that postulate unique mechanisms for this action and benefit. We also present plausible explanations as to why some of the larger statin trials did not report similar such findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425–30.

    Article  PubMed  CAS  Google Scholar 

  2. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995;332:512–21.

    Article  PubMed  CAS  Google Scholar 

  3. Scandinavian Simvastatin Survival Study (4S) Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383–9.

    Article  Google Scholar 

  4. Gotto A, Farmer J. Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol 2003;92:3i–9i.

    Article  PubMed  Google Scholar 

  5. Paradiso-Hardy FL, Gordon WL, Jackevicius CA, Kertland HR, Pearson GJ, Pickering JL, et al. The importance of in-hospital statin therapy for patients with acute coronary syndromes. Pharmacotherapy 2003;23:506–13.

    Article  PubMed  CAS  Google Scholar 

  6. Sever P, Dahlof S, Poulter N, Wedel H, Beevers G, Caulfield M, et al for the Ascot Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58.

    Article  PubMed  CAS  Google Scholar 

  7. Waldman A, Kritharides L. The pleiotropic effects of HMG Co-A reductase inhibitors: their role in osteoporosis and dementia. Drugs 2003;63:139–52.

    Article  PubMed  CAS  Google Scholar 

  8. Weis M, Heeschen C, Glassford A, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002;105:739–45.

    Article  PubMed  CAS  Google Scholar 

  9. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JAF. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999;83:1497–9.

    Article  PubMed  CAS  Google Scholar 

  10. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281–6.

    PubMed  CAS  Google Scholar 

  11. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000;35:549–55.

    Article  PubMed  CAS  Google Scholar 

  12. Prasad GV, Ahmed A, Nash M, Zaltsman J. Blood Pressure reduction with HMG-CoA reductase inhibitors in renal transplant patients. Kidney Int 2003;63:360–4.

    Article  PubMed  CAS  Google Scholar 

  13. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571–6.

    Article  PubMed  CAS  Google Scholar 

  14. Njolstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure and sex differences in myocardial infarction: a 12-year follow-up of the Finnmark Study. Circulation 1996;93:450–6.

    PubMed  CAS  Google Scholar 

  15. Julius S. Clinical implications of pathophysiologic changes in the midlife hypertensive patient. Am Heart J 1991;122:886–91.

    Article  PubMed  CAS  Google Scholar 

  16. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57.

    Article  Google Scholar 

  17. Rosendorff C. Effects of LDL Cholesterol on vascular function. J Hum Hypertens 2002;16:S26–8.

    Article  PubMed  CAS  Google Scholar 

  18. Wassmann S, Laufs U, Baumer A, Muller K, Ahlbory K, Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001;37:1450–7.

    PubMed  CAS  Google Scholar 

  19. Libby P. Inflammation in Atherosclerosis. Inflammation in atherosclerosis. Nature 2002;420:868–74.

    Article  PubMed  CAS  Google Scholar 

  20. Laufs U. Beyond lipid lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 2003;58:719–31.

    PubMed  CAS  Google Scholar 

  21. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduced endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60–8.

    PubMed  Google Scholar 

  22. Tsao PS, Wang B, Buitrago R, Shyy JY-J, Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997;96:934–40.

    PubMed  CAS  Google Scholar 

  23. Liao JK. Endothelium and acute coronary syndromes. Clin Chem 1998;44:1799–808.

    PubMed  CAS  Google Scholar 

  24. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995;377:239–42.

    Article  PubMed  CAS  Google Scholar 

  25. Huang Z, Huang PL, Ma J, Ma J, Meng W, Ayata C, et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-l-arginine. J Cereb Blood Flow Metab 1996;16:981–7.

    Article  PubMed  CAS  Google Scholar 

  26. Huang PL. Disruption of the endothelial nitric oxide synthase gene: effect on vascular response to injury. Am J Cardiol 1998;82:57S–9S.

    PubMed  CAS  Google Scholar 

  27. Ni W, Egashira K, Kataoka C, Kitamoto S, Koyanagi M, Inoue S, et al. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 2001;89:415–21.

    PubMed  CAS  Google Scholar 

  28. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke Prevention by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998;95:8880–5.

    Article  PubMed  CAS  Google Scholar 

  29. Mueck AO, Seeger H, Wallwiener D. Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules. Exp Clin Endocrinol Diabetes 2001;109:181–3.

    Article  PubMed  CAS  Google Scholar 

  30. Feron O, Dessy C, Desager JP, Balligand J-L. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001;103:113–8.

    PubMed  CAS  Google Scholar 

  31. Darley-Usmar VM, McAndrew J, Patel R, Moellering D, Lincoln TM, Jo H, et al. Nitric oxide, free radicals and cell signalling in cardiovascular disease. Biochem Soc Trans 1997;25:925–9.

    PubMed  CAS  Google Scholar 

  32. Li PF, Dietz R, van Harsdorf R. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation 1997;96:3602–9.

    PubMed  CAS  Google Scholar 

  33. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors atorvastatin and simvastatin on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711–9.

    Article  PubMed  CAS  Google Scholar 

  34. Laufs U, LaFata C, Plutzky J, Liao SK. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998;97:1129–35.

    PubMed  CAS  Google Scholar 

  35. Wagner AH, Kohler T, Ruckshloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61–9.

    PubMed  CAS  Google Scholar 

  36. Harrison DG. Endothelial function and oxidative stress. Clin Cardiol 1997;20:II11–7.

    Google Scholar 

  37. Rosendorff C. Pleiotropic effects of statins. In: Kimchi A, editor. Heart disease; new trends in research, diagnosis and treatment. Englewood, NJ: Medimond Medical; 2001. p. 181–186.

    Google Scholar 

  38. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomized placebo controlled trial. Lancet 2002;360:23–33.

    Article  Google Scholar 

  39. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126–31.

    PubMed  CAS  Google Scholar 

  40. Tousoulis D, Antoniades C, Koumallos N, Marinou K, Stefanadi E, Latsios G, et al. Novel therapies targeting vascular endothelium. Endothelium 2006;13:411–21.

    Article  PubMed  CAS  Google Scholar 

  41. Williams JK, Sukhova G, Herrington D, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998;31:684–91.

    Article  PubMed  CAS  Google Scholar 

  42. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844–50.

    PubMed  CAS  Google Scholar 

  43. Van der Wal AC, Backer AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant morphology. Circulation 1994;89:36–44.

    PubMed  Google Scholar 

  44. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: the role of extracellular lipid, macrophages and smooth muscle content. Br Heart J 1993;69:377–81.

    PubMed  CAS  Google Scholar 

  45. Borghi C, Bacchelli S, Degli Espositi D. Pressor and metabolic correlates to long-term development of stable hypertension in borderline hypertensive patients. J Hypertens 1997;15:S111.

    Google Scholar 

  46. Borghi C, Veronesi M, Bacchelli S, Esposti DD, Cosentino E, Ambrosioni E. Serum cholesterol levels, blood pressure response to stress and incidence of stable hypertension in young subjects with high normal blood pressure. J Hypertens 2004 Feb; 22(2):265–72.

    Article  Google Scholar 

  47. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205–51.

    PubMed  CAS  Google Scholar 

  48. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth cells. Circ Res 1994;74:1141–8.

    PubMed  CAS  Google Scholar 

  49. Ng LL, Davies JE, Wojcikiewicz RJ. 3-Hydroxy-3-methyl glutaryl coenzyme A reductase inhibition modules vasopressin-stimulated Ca2+ responses in rat A10 vascular smooth muscle cells. Circ Res 1994;74:173–81.

    PubMed  CAS  Google Scholar 

  50. PPP Project Investigators. Design, rationale and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project: a combined analysis of three large scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 1995;76:899–905.

    Article  Google Scholar 

  51. Pitt B, Waters D, Brown VW, van Boven AJ, Schwartz L, Title LM, Eisenberg D, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341:70–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Internal Medicine, Bronx Veterans Affairs Medical Center and the Mount Sinai School of Medicine, Bronx, NY, USA

    Vineet Chopra & Palak U. Choksi

  2. Division of Cardiology, State University of New York-Downstate Medical Center, Brooklyn, NY, USA

    Erdal Cavusoglu

Authors
  1. Vineet Chopra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Palak U. Choksi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erdal Cavusoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vineet Chopra.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chopra, V., Choksi, P.U. & Cavusoglu, E. Beyond Lipid Lowering: The Anti-Hypertensive Role of Statins. Cardiovasc Drugs Ther 21, 161–169 (2007). https://doi.org/10.1007/s10557-007-6025-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-007-6025-3

Key words

Search

Navigation